UPCC 29424 Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase 1 (Ph1) Study of SNDX-5613 + Gilteritinib
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2.1 (Primary Endpoints). Please refer to Protocol Section 2.2 (Secondary Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
09 Oct 2024.
Study ID: 856170
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
